{
  "docId": "019de516-a80e-7369-bef2-cb942c391804",
  "docSlug": "7dbeec795af717930d34b2c0014ea723",
  "documentTitle": "Oculis | Results Presentation Deck | 33 slides",
  "authorId": "oculis",
  "authorName": "Oculis",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 29,
  "pageCount": 33,
  "prevPage": 28,
  "nextPage": 30,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de516-a80e-7369-bef2-cb942c391804/29",
  "deckHref": "/decks/019de516-a80e-7369-bef2-cb942c391804",
  "deckJsonHref": "/decks/019de516-a80e-7369-bef2-cb942c391804.json",
  "deckAnchorHref": "/decks/019de516-a80e-7369-bef2-cb942c391804#slide-29",
  "components": [
    {
      "bbox": {
        "h": 0.049,
        "w": 0.118,
        "x": 0.847,
        "y": 0.04
      },
      "kind": "image",
      "text": "Oculis",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f78903c4-0f47-4c2e-b494-b30977584bca",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.049,
        "w": 0.939,
        "x": 0.026,
        "y": 0.918
      },
      "kind": "source-note",
      "text": "AMD; age-related macular degeneration; DR: diabetic retinopathy; RVO: retinal vein occlusion. OCS-01 is based on the OPTIREACH® technology, OCS-02 is a single chain antibody fragment (ScFv) against TNFα and OCS-05 is a SGK-2 activator peptidomimetic small molecule with novel MoA targeting the activation of the trophic factor pathways.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "67879ee1-c2e4-4d0c-89d7-b10f951b8f6e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.71,
        "w": 0.945,
        "x": 0.026,
        "y": 0.149
      },
      "kind": "table",
      "text": "Product Candidate(s) Investigational Indication(s) Pre-clinical Phase 1 Phase 2 Phase 3 Next Catalysts 2023 2024 OCS-01 Optireach® technology DIABETIC MACULAR EDEMA 1º endpt. met Stage 1 Ph3 INFLAMMATION AND PAIN FOLLOWING OCULAR SURGERY 1º endpt. met Ph3 NDA CYSTOID MACULAR EDEMA PoC readout OCS-02 Anti TNF DRY EYE DISEASE Ph2b readout UVEITIS Ph2b readout OCS-05 SGK2 Activator ACUTE OPTIC NEURITIS PoC readout GLAUCOMA GEOGRAPHIC ATROPHY DIABETIC RETINOPATHY NEUROTROPHIC KERATITIS OCS-03 CORNEAL NV, PTERYGIUM OCS-04 CORNEAL TRANSPLANT (Undisclosed) Wet-AMD, RVO, DR",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a5a460e2-19be-48cd-8482-5373f654ddcb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.602,
        "x": 0.026,
        "y": 0.05
      },
      "kind": "title",
      "text": "Innovative, Diversified and Late-stage Pipeline",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "28490ab9-2ada-4ee1-8d36-63a26003ccb8",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}